|
|
Chemoprevention Agent Development Research Group
Description: Information on efficacy and safety studies for various chemopreventive agents. Activities include cancer preventive agent discovery through: - Screening profiles
- Preclinical efficacy and toxicity testing
- Pharmaceutical chemistry and manufacturing
- Investigational New Drug Applications
- Phase 1 clinical studies
Chemoprevention has been studied most extensively in animal models for cancer of the skin (non-melanoma), mammary gland, urinary bladder, colon, and prostate. Effective chemoprevention has also been demonstrated in animal models for cancers of the lung, oral cavity, esophagus, pancreas and other epithelial cancers. Anticarcinogenic activity has been demonstrated for a highly diverse group of biological and chemical agents, for example: retinoids (natural and synthetic analogs of vitamin A), plant phenolics (green and black tea, flavonoids, soy isoflavones, curcumin), hormone antagonists (tamoxifen, raloxifene and related antiestrogens), inhibitors of hormone synthesis (vorozole, finasteride), inhibitors of polyamine biosynthesis (difluoromethylornithine (DFMO)), Phase II enzyme inducers (oltipraz, sulforaphan, garlic sulfides); antiinflammatory drugs (aspirin, sulindac, COX-2 inhibitors, budesonide), anti-oxidants (lycopene, carotenoids).
Web Site: http://dcp.cancer.gov/programs-resources/groups/cad
Contact: Vernon E. Steele, Ph.D., M.P.H; steelev@mail.nih.gov
This page last updated 2007-11-08 14:01:36
|